Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Uvea Melanoma
75%
Retinoblastoma
70%
Agents Acting on the Eye
31%
Malignant Neoplasm
30%
Eye Toxicity
27%
Oncology
26%
Metastatic Carcinoma
26%
Tumor
24%
Radiation Therapy
21%
Arm
21%
Von Hippel-Lindau Disease
21%
Metastatic Uvea Melanoma
20%
Cancer
19%
Diseases
19%
Oncologist
18%
Immunotherapy
17%
Intraocular Lymphoma
16%
Oral
16%
Neoplasm
16%
Enucleation
15%
Adverse Event
14%
Cryotherapy
14%
Immune-Related Adverse Events
14%
Immune Checkpoint Inhibitor
12%
Children at Risk
12%
Hemangioblastoma
11%
Vincristine
11%
Genetic Screening
10%
Eye Melanoma
9%
Carboplatin
9%
Intraarterial Drug Administration
9%
Overall Survival
9%
Vitreous
9%
Ruthenium 106
8%
Hypoxia Inducible Factor
8%
Prothrombin
8%
Subgroup Analysis
8%
Anticancer Drug
8%
Graft Versus Host Reaction
8%
Ocular Oncology
8%
External Beam Radiotherapy
8%
Optic Nerve
8%
Melanoma
7%
Choroid
7%
Side Effect
7%
Melanoma Skin Cancer
7%
Echography
7%
Drug Megadose
6%
Ophthalmology
6%
Clinical Trial
6%
Keyphrases
Retinoblastoma
100%
Uveal Melanoma
84%
Tumor
31%
Ocular Toxicity
26%
Bilateral Retinoblastoma
25%
Von Hippel-Lindau Disease
22%
Children's Oncology Group
19%
Metastatic Melanoma
18%
Clinical Trials
17%
Ocular Side Effects
16%
Metastatic Uveal Melanoma
16%
Ophthalmologist
16%
Enucleation
15%
Primary Intraocular Lymphoma
14%
Cryotherapy
14%
Immune-related Adverse Events
14%
High Risk
13%
Children at Risk
12%
Immune Checkpoint Inhibitors
12%
Targeted Cancer Therapy
12%
Group Studies
12%
Chemotherapy
11%
Radiotherapy
11%
Oncologists
11%
Intraocular Tumor
10%
Metastatic Disease
10%
Ocular Oncology
10%
Melanoma Patients
10%
Oncology
9%
Genetic Testing
9%
Ipilimumab
9%
Intra-arterial Chemotherapy
9%
Carboplatin
9%
Risk Factors
9%
Clinical Data
8%
Adjuvant Therapy
8%
Ophthalmic Manifestations
8%
Overall Survival
8%
Adverse Events
8%
Oral Adverse Events
8%
Phase I Trial
8%
Childrens
8%
Subgroup Analysis
8%
Tertiary Cancer Center
8%
106Ru
8%
Hypoxia-inducible Factor 2
8%
Otologic
8%
Belzutifan
8%
Management Suggestions
8%
Immune-related
8%